详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Shanghai Chest Hospital, Shanghai/ China, [2]Tianjin Medical University Cancer Hospital, Tianjin/China, [3]Henan Province Tumor Hospital, Henan/ China, [4]Peking Union Medical College Hospital, Beijing/ China, [5]Linyi City Tumor Hospital, Linyi/China, [6]Shandong Province Tumor Hospital, Jinan/Christmas Island, [7]First Affiliated Hospital of Guangzhou Medical University, Guangzhou/China, [8]Chinese Academy of Medical Sciences Cancer Hospital, Beijing/China, [9]Jilin Province Tumor Hospital, Changchun/China, [10]Lanzhou Military General Hospital, Lanzhou/China, [11]Qilu Hospital, Shandong University, Qilu/China, [12]Hunan Province Tumor Hospital, Changsha/China, [13]First Affiliated Hospital of Xi’An Jiaotong University, Xian/China, [14]Tang Du Hospital, Xian/China, [15]Yunnan Province Tumor Hospital, Kunming/China, [16]Capital Medical University, Beijing Chest Hospital, Beijing/China, [17]The First Affiliated Hospital of Zhejiang University, Hangzhou/China, [18]Jiangxi Province Tumor Hospital, Nanchang/China, [19]Chongqing Cancer Hospital, Chongqing/China, [20]Affiliated Cancer Hospital of Xinjiang Medical University, Wulumuqi/China, [21]Harbin Medical University Affiliated Tumor Hospital, Harbin/China, [22]First Affiliated Hospital of Shantou University Medical College, Shantou/China, [23]Second Affiliated Hospital of Nanchang University, Nanchang/China, [24]The Second Affiliated Hospital of Zhejiang University, Hangzhou/China, [25]Fujian Province Tumor Hospital, Fuzhou/China, [26]Beijing Friendship Hospital, Beijing/China, [27]Tianjin Medical University General Hospital, Tianjin/China, [28]Liaoning Provincial Tumor Hospital, Sheyang/China, [29]The Affiliated Hospital of Qingdao University, Qingdao/China, [30]Fourth Hospital of Hebei Medical University, Hebei/China, [31]Xuzhou Medical College Hospital, Xuzhou/China

出处：

DOI：

ISSN：

关键词： NSCLC Anlotinib multi-targeted tyrosine kinase inhibitor

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2015]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 21.1 最新五年平均[2021-2025] 16.5 出版当年[2015版] 5.04 出版当年五年平均[2011-2015] 4.932 出版前一年[2014版] 5.282 出版后一年[2016版] 6.595

第一作者：

第一作者单位： [1]Shanghai Chest Hospital, Shanghai/ China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

文献详情

相关文献